T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific genetic ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

OLD man whose cancer has returned for a third time is hoping for a stem cell donor to enable him to have the treatment.

The Lymphoma Research Foundation, the nation's largest nonprofit organization devoted to funding innovative lymphoma research and serving the lymphoma community, has awarded 24 new research grants in ...

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A newly renovated multi-family home in Brookline is offering free stays to families who travel to the Boston area because a ...

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).